Cocrystal Pharma Set to Present Key Clinical Milestones Soon
![Cocrystal Pharma Set to Present Key Clinical Milestones Soon](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Cocrystal Pharma Presents Near-Term Clinical Milestones at Investment Conferences
BOTHELL, Wash. — Cocrystal Pharma, Inc. (Nasdaq: COCP) management announces its participation in the upcoming Virtual Investor Summit Microcap Forum and the H.C. Wainwright 26th Annual Global Investment Conference.
“We look forward to showcasing key near-term clinical milestones at these prominent investment conferences,” said James Martin, CFO and co-CEO of Cocrystal. “We expect to report topline results in the near future from our influenza A Phase 2a challenge study regarding our novel oral PB2 inhibitor CC-42344, with a final report anticipated to be completed in the following year. Additionally, we are excited to announce that topline results from the Phase 1 multiple-ascending cohorts for our novel oral protease inhibitor CDI-988, targeting norovirus and coronavirus infections, are expected by the end of this year or early next year.”
Upcoming Conferences
Virtual Investor Summit Microcap Forum
The presentation and Q&A session is scheduled to begin soon, detailing Cocrystal's latest developments.
H.C. Wainwright 26th Annual Global Investment Conference
An on-demand presentation will be available on the conference platform, allowing participants to engage with the management team both in-person and virtually. This event represents a crucial opportunity for institutional investors and industry professionals to connect with the company.
Pipeline Products Overview
CC-42344 – Pandemic and Seasonal Influenza A PB2 Inhibitor
CC-42344 represents Cocrystal's novel, broad-spectrum antiviral candidate, specifically designed to combat pandemic and seasonal influenza A. This drug inhibits the replication of the influenza A virus by binding to a conserved PB2 site. The compound is currently undergoing a Phase 2a challenge study in healthy volunteers, demonstrating promising safety and pharmacokinetics in earlier trials.
CDI-988 – Protease Inhibitor for Noroviruses and Coronaviruses
CDI-988 is an innovative protease inhibitor targeting norovirus and coronaviruses, including variants of SARS-CoV-2. The design of CDI-988 aims to provide broad-spectrum antiviral activity through a unique structural approach, undergoing a randomized Phase 1 trial evaluating its safety and pharmacodynamics.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel antiviral therapeutics targeting the replication of various viruses, including influenza, noroviruses, coronaviruses, and hepatitis C. Utilizing advanced structure-based technologies and expertise, Cocrystal aims to produce first- and best-in-class antiviral medications.
Investor and Media Contact Information
Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com
Frequently Asked Questions
1. What events will Cocrystal Pharma be presenting at?
Cocrystal Pharma will present at the Virtual Investor Summit Microcap Forum and the H.C. Wainwright 26th Annual Global Investment Conference.
2. What are the key milestones Cocrystal Pharma plans to showcase?
The company plans to showcase topline results from its influenza A Phase 2a challenge study and Phase 1 trials for its antiviral candidates, CC-42344 and CDI-988.
3. What is CC-42344 designed to treat?
CC-42344 is an antiviral candidate designed to treat pandemic and seasonal influenza A by inhibiting the virus's replication process.
4. What conditions does CDI-988 target?
CDI-988 is focused on treating infections caused by noroviruses and coronaviruses, including variants of SARS-CoV-2.
5. How can investors contact Cocrystal Pharma?
Investors can reach out via LHA Investor Relations by contacting Jody Cain at 310-691-7100 or through email at jcain@lhai.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/